← Back to Search

SUFU Clinical Care Pathway for Overactive Bladder for Overactive Bladder (OAB Telemed Trial)

N/A
Waitlist Available
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Idiopathic overactive bladder diagnosis, both OAB wet and OAB dry
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

OAB Telemed Trial Summary

This trial is testing whether telemedicine (video conferencing) is as effective as in-person visits for treating OAB.

Eligible Conditions
  • Overactive Bladder

OAB Telemed Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

OAB Telemed Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient Satisfaction
Secondary outcome measures
Accumulated cost of visit to patient (Cost)
Accumulated time of visit for patient (Time)
Incidence of Treatment-emergent adverse events (safety and tolerability)
+2 more

OAB Telemed Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Telemedicine ArmExperimental Treatment2 Interventions
Patients will receive OAB treatment as described in the SUFU OAB clinical care pathway but all visits will be performed via telemedicine
Group II: Traditional In-Person Clinic Visit ArmPlacebo Group1 Intervention
Patients will receive overactive bladder (OAB) treatment as described in the Society for Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB clinical care pathway. These patients will have all visits in-person

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,538 Previous Clinical Trials
10,266,854 Total Patients Enrolled
~45 spots leftby Jun 2025